211 related articles for article (PubMed ID: 34811968)
1. Assessing the predictive performance of population pharmacokinetic models for intravenous polymyxin B in critically ill patients.
Hanafin PO; Nation RL; Scheetz MH; Zavascki AP; Sandri AM; Kwa AL; Cherng BPZ; Kubin CJ; Yin MT; Wang J; Li J; Kaye KS; Rao GG
CPT Pharmacometrics Syst Pharmacol; 2021 Dec; 10(12):1525-1537. PubMed ID: 34811968
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetics of polymyxin B in patients with liver dysfunction.
Li X; Cheng Y; Chen B; Chen Y; Huang Y; Zhang B; Que W; Liu M; Zhang H; Qiu H
Br J Clin Pharmacol; 2023 Dec; 89(12):3561-3572. PubMed ID: 37461291
[TBL] [Abstract][Full Text] [Related]
3. Population Pharmacokinetics of Polymyxin B in Acutely Ill Adult Patients.
Miglis C; Rhodes NJ; Avedissian SN; Kubin CJ; Yin MT; Nelson BC; Pai MP; Scheetz MH
Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29311071
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens.
Sandri AM; Landersdorfer CB; Jacob J; Boniatti MM; Dalarosa MG; Falci DR; Behle TF; Bordinhão RC; Wang J; Forrest A; Nation RL; Li J; Zavascki AP
Clin Infect Dis; 2013 Aug; 57(4):524-31. PubMed ID: 23697744
[TBL] [Abstract][Full Text] [Related]
5. The population pharmacokinetics and dose optimization of polymyxin B in critically ill patients with or without extracorporeal membrane oxygenation.
Ye Q; Wang Q; Chen W; Zhang R; Chen Z; Li P; Zhang X; Zhan Q; Wang C
J Clin Pharm Ther; 2022 Oct; 47(10):1608-1618. PubMed ID: 35716048
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic/pharmacodynamic adequacy of polymyxin B against extensively drug-resistant Gram-negative bacteria in critically ill, general ward and cystic fibrosis patient populations.
Xie J; Roberts JA; Lipman J; Cai Y; Wang H; Zhao N; Xu X; Yang S; Li Y; Zhang K
Int J Antimicrob Agents; 2020 Jun; 55(6):105943. PubMed ID: 32184115
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics of polymyxin B and dosage strategy in critically ill patients with/without continuous renal replacement therapy.
Luo X; Zhang Y; Liang P; Zhu H; Li M; Ding X; Zhang J
Eur J Pharm Sci; 2022 Aug; 175():106214. PubMed ID: 35609779
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetic and optimization of polymyxin B dosing in adult patients with various renal functions.
Yu XB; Jiao Z; Zhang CH; Dai Y; Zhou ZY; Han L; Wen X; Sheng CC; Lin GY; Pan JY
Br J Clin Pharmacol; 2021 Apr; 87(4):1869-1877. PubMed ID: 33002196
[TBL] [Abstract][Full Text] [Related]
9. External evaluation of published population pharmacokinetic models of polymyxin B.
Li YQ; Chen KF; Ding JJ; Tan HY; Yang N; Lin YQ; Wu CF; Xie YL; Yang GP; Liu JJ; Pei Q
Eur J Clin Pharmacol; 2021 Dec; 77(12):1909-1917. PubMed ID: 34342716
[TBL] [Abstract][Full Text] [Related]
10. Systematic Evaluation of Pharmacokinetic Models for Model-Informed Precision Dosing of Meropenem in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy.
Schatz LM; Brinkmann A; Röhr A; Frey O; Greppmair S; Weinelt F; Zoller M; Scharf C; Hempel G; Liebchen U
Antimicrob Agents Chemother; 2023 May; 67(5):e0010423. PubMed ID: 37125925
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetics and evaluation of the predictive performance of pharmacokinetic models in critically ill patients receiving continuous infusion meropenem: a comparison of eight pharmacokinetic models.
Dhaese SAM; Farkas A; Colin P; Lipman J; Stove V; Verstraete AG; Roberts JA; De Waele JJ
J Antimicrob Chemother; 2019 Feb; 74(2):432-441. PubMed ID: 30376103
[TBL] [Abstract][Full Text] [Related]
12. Aerosolized Polymyxin B for Treatment of Respiratory Tract Infections: Determination of Pharmacokinetic-Pharmacodynamic Indices for Aerosolized Polymyxin B against Pseudomonas aeruginosa in a Mouse Lung Infection Model.
Lin YW; Zhou Q; Onufrak NJ; Wirth V; Chen K; Wang J; Forrest A; Chan HK; Li J
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559256
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of intravenous polymyxin B in critically ill patients.
Zavascki AP; Goldani LZ; Cao G; Superti SV; Lutz L; Barth AL; Ramos F; Boniatti MM; Nation RL; Li J
Clin Infect Dis; 2008 Nov; 47(10):1298-304. PubMed ID: 18840079
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and pharmacodynamics of polymyxin B and proposed dosing regimens in elderly patients with multi-drug-resistant Gram-negative bacterial infections.
Wang P; Liu D; Sun T; Zhang X; Yang J
Int J Antimicrob Agents; 2022; 60(5-6):106693. PubMed ID: 36375775
[TBL] [Abstract][Full Text] [Related]
15. Population Pharmacokinetic Study of the Suitability of Standard Dosing Regimens of Amikacin in Critically Ill Patients with Open-Abdomen and Negative-Pressure Wound Therapy.
Carrié C; Delzor F; Roure S; Dubuisson V; Petit L; Molimard M; Breilh D; Biais M
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31964795
[TBL] [Abstract][Full Text] [Related]
16. Impact of nutritional factors on in vitro PK/PD modelling of polymyxin B against various strains of Acinetobacter baumannii.
Lacroix M; Moreau J; Zampaloni C; Bissantz C; Shirvani H; Marchand S; Couet W; Chauzy A
Int J Antimicrob Agents; 2024 Jul; 64(1):107189. PubMed ID: 38697578
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetic analysis and dosing optimization of polymyxin B in critically ill patients.
Liang D; Liang Z; Deng G; Cen A; Luo D; Zhang C; Ni S
Front Pharmacol; 2023; 14():1122310. PubMed ID: 37063299
[No Abstract] [Full Text] [Related]
18. Evaluation of the performance of a prior tacrolimus population pharmacokinetic kidney transplant model among adult allogeneic hematopoietic stem cell transplant patients.
Zhu J; Campagne O; Torrice CD; Flynn G; Miller JA; Patel T; Suzuki O; Ptachcinski JR; Armistead PM; Wiltshire T; Mager DE; Weiner DL; Crona DJ
Clin Transl Sci; 2021 May; 14(3):908-918. PubMed ID: 33502111
[TBL] [Abstract][Full Text] [Related]
19. Predictive performance of a gentamicin population pharmacokinetic model in neonates receiving full-body hypothermia.
Sampson MR; Frymoyer A; Rattray B; Cotten CM; Smith PB; Capparelli E; Bonifacio SL; Cohen-Wolkowiez M
Ther Drug Monit; 2014 Oct; 36(5):584-9. PubMed ID: 25225917
[TBL] [Abstract][Full Text] [Related]
20. Plasma and target-site subcutaneous tissue population pharmacokinetics and dosing simulations of cefazolin in post-trauma critically ill patients.
Roberts JA; Udy AA; Jarrett P; Wallis SC; Hope WW; Sharma R; Kirkpatrick CM; Kruger PS; Roberts MS; Lipman J
J Antimicrob Chemother; 2015 May; 70(5):1495-502. PubMed ID: 25608584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
